Journal of Pharmacology and Pharmacotherapeutics

REVIEW ARTICLE
Year
: 2021  |  Volume : 12  |  Issue : 3  |  Page : 110--114

Effect of homoharringtonine as a combined regimen for acute myeloid leukemia


Abinaya Muralidharan1, J Julius Xavier Scott2, Leena Dennis Joseph3, Srikanth Jeyabalan1 
1 Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India
2 Department of Pediatric Medicine, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India
3 Department of Pathology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India

Correspondence Address:
Srikanth Jeyabalan
Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Porur, Chennai, Tamil Nadu
India

Homoharringtonine (HHT), a cephalotaxus alkaloid has shown promising results in the treatment of several hematological disorders such as chronic myeloid leukemia, acute myeloid leukemia (AML), and myelodysplastic syndrome. It is known for its unique mechanism of action by which it prevents the initial elongation step of protein biosynthesis. Hence, it is used in hematological malignancies where it synergistically potentiates the action of other drugs and induces apoptosis. The relevant studies published were searched using an electronic database from 2002 to 2019. The articles published in English were only considered. Search engines such as PubMed, MEDLINE, Google Scholar, and Semantic scholar were used. In this review, we have discussed the effect of HHT in combination with other chemotherapeutic agents for AML with or without genetic mutation specification and the future perspective of these regimens. Although standard treatment options exist for most of these diseases, still cure rates are low with reported morbidity and the drug resistance emergence is pervasive. Thus, novel treatment approaches are crucial for better outcome. Alternative regimens together with HHT have not been a standard practice, although they have shown a very good potential in AML patients. Many of the combinations were also proved to be safe and effective with very low toxic potential. All these data outcomes of various combinations under different scenarios exhibit that HHT has promising results in the treatment of AML which may lead to its approval in the upcoming years.


How to cite this article:
Muralidharan A, Scott J J, Joseph LD, Jeyabalan S. Effect of homoharringtonine as a combined regimen for acute myeloid leukemia.J Pharmacol Pharmacother 2021;12:110-114


How to cite this URL:
Muralidharan A, Scott J J, Joseph LD, Jeyabalan S. Effect of homoharringtonine as a combined regimen for acute myeloid leukemia. J Pharmacol Pharmacother [serial online] 2021 [cited 2021 Nov 28 ];12:110-114
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2021;volume=12;issue=3;spage=110;epage=114;aulast=Muralidharan;type=0